No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification
Stéphane Paul, Nicolas Williet, Stéphane Nancey, Pauline Veyrard, Gilles Boschetti, Jean–Marc Phelip, Bernard Flourié, Xavier Roblin
Topics & Concepts
RegimenMedicineAdalimumabInternal medicinePharmacokineticsGastroenterologySurgeryDiseaseInflammatory Bowel DiseaseBiosimilars and Bioanalytical MethodsMicroscopic Colitis